Diagnostic performance of 18F‐fluorodeoxyglucose positron emission tomography in the evaluation of glioma. Issue 5 (1st August 2019)
- Record Type:
- Journal Article
- Title:
- Diagnostic performance of 18F‐fluorodeoxyglucose positron emission tomography in the evaluation of glioma. Issue 5 (1st August 2019)
- Main Title:
- Diagnostic performance of 18F‐fluorodeoxyglucose positron emission tomography in the evaluation of glioma
- Authors:
- Shaw, Tristan B
Jeffree, Rosalind L
Thomas, Paul
Goodman, Steven
Debowski, Maciej
Lwin, Zarnie
Chua, Benjamin - Abstract:
- Abstract: Introduction: Identifying glioma grade through imaging allows clinicians to recommend and accurately direct treatment. We sought to quantify the utility of FDG‐PET/CT (18F‐fluorodeoxyglucose positron emission tomography/computed tomography), alone and in combination with MRI, in identifying high‐grade regions of glioma. Methods: This is a retrospective review of patients who had an FDG‐PET/CT performed as part of the workup of suspected glioma or in follow‐up of known glioma. FDG‐PET/CT scans were reviewed and uptake in the identifiable lesion coded as none, diffusely or focally increased. Patients also underwent gadolinium‐enhanced MRI, noting regions of contrast enhancement. Sensitivity, specificity, positive and negative predictive values (PPV and NPV) were calculated for identification of high‐grade histology (WHO III or IV, or metastatic disease) obtained post‐FDG‐PET/CT. Results: Thirty‐three patients had 36 FDG‐PET/CT and MRI scans followed by histological confirmation (biopsy or debulking). Increased FDG uptake demonstrated a sensitivity of 59% and specificity of 79%, PPV of 81% and NPV of 55% for identification of high‐grade histology. MRI demonstrated a sensitivity of 77% and specificity of 86%, PPV of 89% and NPV of 71% for identification of high‐grade histology. Only 64% of MRI and FDG‐PET/CT scan series were concordant. When FDG‐PET/CT and MRI were concordant, a specificity of 100% and PPV of 100% was achieved, however, sensitivity was 79% and NPV wasAbstract: Introduction: Identifying glioma grade through imaging allows clinicians to recommend and accurately direct treatment. We sought to quantify the utility of FDG‐PET/CT (18F‐fluorodeoxyglucose positron emission tomography/computed tomography), alone and in combination with MRI, in identifying high‐grade regions of glioma. Methods: This is a retrospective review of patients who had an FDG‐PET/CT performed as part of the workup of suspected glioma or in follow‐up of known glioma. FDG‐PET/CT scans were reviewed and uptake in the identifiable lesion coded as none, diffusely or focally increased. Patients also underwent gadolinium‐enhanced MRI, noting regions of contrast enhancement. Sensitivity, specificity, positive and negative predictive values (PPV and NPV) were calculated for identification of high‐grade histology (WHO III or IV, or metastatic disease) obtained post‐FDG‐PET/CT. Results: Thirty‐three patients had 36 FDG‐PET/CT and MRI scans followed by histological confirmation (biopsy or debulking). Increased FDG uptake demonstrated a sensitivity of 59% and specificity of 79%, PPV of 81% and NPV of 55% for identification of high‐grade histology. MRI demonstrated a sensitivity of 77% and specificity of 86%, PPV of 89% and NPV of 71% for identification of high‐grade histology. Only 64% of MRI and FDG‐PET/CT scan series were concordant. When FDG‐PET/CT and MRI were concordant, a specificity of 100% and PPV of 100% was achieved, however, sensitivity was 79% and NPV was 75%. Conclusion: The combination of FDG‐PET/CT and gadolinium‐enhanced MRI demonstrated marked improvement in identifying potential high‐grade disease over each modality alone. Increased FDG uptake without gadolinium enhancement rarely occurred and identified high‐grade histology in a small number of patients. Due to limited sensitivity and NPV, a negative FDG‐PET/CT alone, or in combination with MRI, should not guide a decision for observation where surgery would otherwise be recommended. … (more)
- Is Part Of:
- Journal of medical imaging and radiation oncology. Volume 63:Issue 5(2019:Oct.)
- Journal:
- Journal of medical imaging and radiation oncology
- Issue:
- Volume 63:Issue 5(2019:Oct.)
- Issue Display:
- Volume 63, Issue 5 (2019)
- Year:
- 2019
- Volume:
- 63
- Issue:
- 5
- Issue Sort Value:
- 2019-0063-0005-0000
- Page Start:
- 650
- Page End:
- 656
- Publication Date:
- 2019-08-01
- Subjects:
- brain tumour -- fluorodeoxyglucose -- glioma -- magnetic resonance imaging -- positron emission tomography
Radiology, Medical -- Periodicals
Radiology, Medical -- Australasia -- Periodicals
616.0757 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1754-9485 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1754-9485.12929 ↗
- Languages:
- English
- ISSNs:
- 1754-9477
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5017.072080
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11858.xml